depakine retard 500 mg depottabletter
2care4 aps - natriumvalproat, valproinsyre - depottabletter - 500 mg
deprakine retard 300 mg depottabletter
sanofi a/s - natriumvalproat, valproinsyre - depottabletter - 300 mg
everolimus "stada" 2,5 mg tabletter
stada arzneimittel ag - everolimus - tabletter - 2,5 mg
everolimus "sandoz" 2,5 mg tabletter
sandoz a/s - everolimus - tabletter - 2,5 mg
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptika, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
silocalm 1 mg/ml oral suspension
ethypharm - clobazam - oral suspension - 1 mg/ml
epaclob 1 mg/ml oral suspension
ethypharm - clobazam, sorbitoloplØsning 70% - oral suspension - 1 mg/ml
levomethadon "g.l. pharma" 2,5 mg tabletter
g.l. pharma gmbh - levomethadonhydrochlorid - tabletter - 2,5 mg
advagraf
astellas pharma europe bv - tacrolimus - graft afvisning - immunosuppressiva - profylakse af transplantationsafstødning hos voksne nyre- eller levertransplantationsmodtagere. behandling af allograft afvisning resistente over for behandling med andre immunosuppressive lægemidler hos voksne patienter.
briviact (in italy: nubriveo)
ucb pharma sa - brivaracetam - epilepsi - antiepileptika, - briviact er indiceret som supplerende terapi til behandling af partielle anfald med eller uden sekundær generalisering hos voksne og unge patienter fra 16 år med epilepsi.